Literatuur

  1. SmPC tekst Pradaxa.
  2. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259-68. 
  3. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157:805-10.  
  4. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949-56. 
  5. Eriksson BI, Dahl OE, Rosencher N, Clemens A, Hantel S, Kurth AA. Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis. Thromb Res. 2012;130:871-6. 
  6. Clemens A, van Ryn J, Sennewald R, Yamamura N, Stangier J, Feuring M, et al. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. Eur J Clin Pharmacol. 2012;68:607-16. 
  7. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. 
  8. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation. Circulation. 2015;131:157-64.
  9. Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation. 2013;128:237-43.
  10. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjoth F, Rosenzweig M, Lip GYH. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med. 2014;127:650-6.
  11. Chan NC, Coppens M, Hirsh J, Ginsberg JS, Weitz JI, Vanassche T, et al. Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost. 2015;13:353-9.
  12. Lip GYH, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S. Patient outcomes using the European label for dabigatran: A post-hoc analysis from the RE-LY database. Thromb Haemost. 2014;111:933-42.
  13. Pradaxa product monograph Canada. 2010.
  14. Boehringer Ingelheim briefing document FDA. 2010.
  15. Mochalina N, Juhlin T, Platonov PG, Svensson PJ, Wieloch M. Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice. Thromb Res. 2015;135:1070-4.
  16. Reilly PA, Connolly SJ, Ezekowitz MD, Haertter S, Noack H, Wallentin L, et al. Concomitant use of P-glycoprotein inhibitors with dabigatran or warfarin in the RE-LY trial. Eur Hear J. 2011;32(Suppl 1):6.
  17. Hartter S, Koenen-Bergmann M, Sharma A, Nehmiz G, Lemke U, Timmer W, et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol. 2012;74:490-500.
  18. Stangier J, Stahle H, Rathgen K, Roth W, Reseski K, Kornicke T. Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, With Coadministration of Digoxin. J Clin Pharmacol. 2012;52:243-50.
  19. Barco S, Coppens M, van den Dool EJ, van de Kerkhof D, Stroobants AK, Middeldorp S. Successful co-administration of dabigatran etexilate and protease inhibitors ritonavir/lopinavir in a patient with atrial fibrillation. Thromb Haemost. 2014;112:836-8.
  20. Fisher M, Loscalzo J. The perils of combination antithrombotic therapy and potential resolutions. Circulation. 2011;123:232-5.
  21. Tapp LD, Lip GY, Lane DA. Optimal antithrombotic therapy in patients receiving long-term oral anticoagulation requiring percutaneous coronary intervention: “triple therapy” or “triple threat.” Chest. 2011;139:240-2.
  22. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127:634-40.
  23. Lobmeyer M, Giessmann T, Strelkowa N, Wolzt M, Gouya G, Gansser D, et al. Pharmacokinetic and pharmacodynamic effects of ticagrelor and dabigatran etexilate coadministration in healthy male volunteers. Eur Heart J. 2014;35(Suppl 1):P14-13762.
  24. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H, Hacke W, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467-507.
  25. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-27.
  26. Werkgroep NOACs van de wetenschappelijke verenigingen en Orde van Medisch Specialisten. Leidraad begeleide introductie nieuwe orale antistollingsmiddelen. 2012.
  27. Hemoclot product informatie. 2010.
  28. Informatie voorschrijvende artsen dabigatran. 2011.
  29. Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res. 2011;127:457-65.
  30. EMA. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/05/ WC500127777.pdf. 2013. p. pagina 29.
  31. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-52.
  32. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709-18.
  33. FDA Drug Safety Communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa (dabigatran). http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm.
  34. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368:1272-4.
  35. Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128:2325-32.
  36. Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost. 2013;109:596-605.
  37. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-9.
  38. Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015;373:511-20.
  39. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123:131-6.
  40. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-429.
  41. Eikelboom J, Connolly S, Brueckmann M, Granger C, Kappetein A, Mack M, et al. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. N Engl J Med. 2013;369:1206-14.
  42. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170:1433-41.
  43. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-7.
  44. Glund S, Stangier J, Schmohl M, Gansser D, Norris S, Van Ryn J, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: A randomised, placebo-controlled, double-blind phase 1 trial. Lancet. Elsevier Ltd; 2015;386:680-90.
  45. Kappelle LJ, Hofmeijer J, Chamuleau SA, van Nieuwenhuizen KM, Hemels ME, Klijn CJ. Hervatten van antistolling na een hersenbloeding. Ned Tijdschr Geneeskd. 2015;159:A8507.
  46. Diener HC, Easton JD, Hankey GJ, Hart RG. Novel oral anticoagulants in secondary prevention of stroke. Best Pract Res Clin Haematol. 2013;26:131-9.
  47. NVA. Richtlijn Neuraxisblokkade en Antistolling. Inclusief: perifere zenuw en interventionele pijntechnieken. 2014.
  48. de Jong JS, Vink R, Henny C, Levi M, van den Brink RB, Kamphuisen PW. Perioperatieve onderbreking van antistollingsmiddelen: Praktische aanbevelingen. Ned Tijdschr Geneeskd. 2009;153:A83.
  49. CBO-Richtlijn Diagnostiek, preventie en behandeling van veneuze trombo-embolie en secundaire preventie van arteriele trombose. 2008.
  50. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):381S-453S.
  51. ACTA-richtlijn: Beleid bij tandheelkundige ingrepen tijdens antitrombotische behandeling. (www.tandartsennet.nl). 2012.
  52. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:271-47.
  53. Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011;155:660-7.
  54. Sinnaeve PR, Brueckmann M, Clemens A, Oldgren J, Eikelboom J, Healey JS. Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. J Intern Med. 2012;271:15-24.
  55. Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol. 2013;70:1486-90.
  56. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67.
  57. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):141S - 159S.
  58. Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006;54:1231-6.
  59. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689-96.
  60. Palareti G, Hirsh J, Legnani C, Manotti C, D’Angelo A, Pengo V, et al. Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Intern Med. 2000;160:470-8.
  61. Leerboek Interne Geneeskunde. Bohn Stafleu van Loghum; 2011.
  62. Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005;118:612-7.
  63. Garwood CL, Corbett TL. Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. Ann Pharmacother. 2008;42:523-32.
  64. Donze J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med. 2012;125:773-8.
  65. Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012;43:1511-7.
  66. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive Impairment Associated With Atrial Fibrillation: A Meta-analysis. Ann Intern Med. 2013;158(5 Pt 1):338-46.
  67. Gurwitz JH, Monette J, Rochon PA, Eckler MA, Avorn J. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med. 1997;157:978-84.
  68. Flaker GC, Pogue J, Yusuf S, Pfeffer MA, Goldhaber SZ, Granger CB, et al. Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ Cardiovasc Qual outcomes. 2010;3:277-83.
  69. Healey JS, Eikelboom J, Wallentin L, Ezekowitz MD, Connolly SJ, Reilly P, et al. Effect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: an analysis from the RE-LY study. J Am Coll Cardiol. 2010;55(10A):A4.E37.
  70. Brambatti M, Darius H, Oldgren J, Clemens A, Noack HH, Brueckmann M, et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol. Elsevier B.V.; 2015;196:127-31.
  71. Ferreira J, Ezekowitz MD, Connolly SJ, Reilly PA, Clemens A, Brueckmann M, et al. Dabigatran Compared with Warfarin in Patients with Atrial Fibrillation and Symptomatic Heart Failure: A Subgroup Analysis of the RE-LY Trial. Circulation. 2011;124(abstract10956).
  72. Nagarakanti R, Wallentin L, Noack H, Brueckmann M, Reilly P, Clemens A, et al. Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). Am J Cardiol. 2015;116:1204-9.
  73. Ezekowitz ME, Parise H, Connolly SJ, Brueckmann M, Kleine E, Clemens A, et al. The use of dabigatran according to body mass index: the RE-LY experience. Eur Heart J. 2014;35(Suppl 1):P14-13551 (Abstract P6257).
  74. Vranckx P, Verheugt FW, de Maat MP, Ulmans VA, Regar E, Smits P, et al. A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients. EuroIntervention. 2013;8:1052-60.
  75. Bapat P, Kedar R, Lubetsky A, Matlow JN, Aleksa K, Berger H, et al. Transfer of Dabigatran and Dabigatran Etexilate Mesylate Across the Dually Perfused Human Placenta. Obstet Gynecol. 2014;123:1256-61.
  76. Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost. 2015;114:150-7.
  77. Zweedse vereniging voor trombose en hemostase (SSTH). Klinisch advies voor de behandeling met nieuwe orale anticoagulantia. 2012.
  78. Farmacotherapeutisch kompas: geactiveerde kool [A07BA01].
  79. Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M. Hemodialysis for the treatment of dabigatran-associated bleeding: A case report and systematic review. J Thromb Haemost. 2015;13:1790-8.
Zoeken  
vorige hoofdstuk   |   volgende hoofdstuk